Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (1008)	4/23/1999 10:42:00 PM
From: software salesperson	Read Replies (1) \| Respond to of 3202

can anyone explain how the pending litigation with affymetrix translates into a revenue shortfall? is it customer uncertainty or is incyte not pursuing certain revenue because of the pending litigation? thanks. sales

To: Rocketman who wrote (1008)	4/29/1999 9:23:00 PM
From: lasearch	Read Replies (1) \| Respond to of 3202

I tend to agree with you. And while I've done well trading INCY, I think now is the time to be accumulating for the long term as the stock continues to drift down on ho-hum volume.

To: Rocketman who wrote (1008)	4/30/1999
From: PashaBear	Read Replies (1) \| Respond to of 3202

Anyone have a reasoned response to this "dissing" of INCY on the AFFX thread? Is what the poster says possibly right? PB (long both, but much more INCY) Additionally, this is a leading company in the genomics field, which is relatively "hot", although not compared with the nets. This "Hotness" is verified by the recent price moves in affx and mlnm. Additionally, Incyte in it's quarterly gave indications that affx might be winning the patent war by stating that 99 revenues would not meet expectations due to affx patent dispute. Another possible factor is the fact that a lot of people have been dumping INCY lately have possibly shifted that cash into affx. At any rate, a lot of people have realized for a long time that this company had tremendous potential. With recent events (ie revenue growth, flurry of deals, and possible edge over INCY in patent disputes) this may be a stock whose time has come. The technicals backing this up are moving over 41 today after several days of high volume. This is why I predicted the price increase to come in the next week or so, due to the chart. However, I am not really a chartist, so take that with a grain of salt. We'll see.